Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms
Polycythemia vera (PV) and essential thrombocythemia (ET) are two Philadelphia-negative myeloproliferative neoplasms (MPN) associated with an acquired mutation in the JAK2 tyrosine kinase gene. There is a rare incidence of progression to myelofibrosis and myeloid metaplasia in both disorders, which...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/tsw.2011.108 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849304268400492544 |
|---|---|
| author | Fabrizio Vianello Anna Battisti Giuseppe Cella Marina Marchetti Anna Falanga |
| author_facet | Fabrizio Vianello Anna Battisti Giuseppe Cella Marina Marchetti Anna Falanga |
| author_sort | Fabrizio Vianello |
| collection | DOAJ |
| description | Polycythemia vera (PV) and essential thrombocythemia (ET) are two Philadelphia-negative myeloproliferative neoplasms (MPN) associated with an acquired mutation in the JAK2 tyrosine kinase gene. There is a rare incidence of progression to myelofibrosis and myeloid metaplasia in both disorders, which may or may not precede transformation to acute myeloid leukemia, but thrombosis is the main cause of morbidity and mortality. The pathophysiology of thrombosis in patients with MPN is complex. Traditionally, abnormalities of platelet number and function have been claimed as the main players, but increased dynamic interactions between platelets, leukocytes, and the endothelium do probably represent a fundamental interplay in generating a thrombophilic state. In addition, endothelial dysfunction, a well-known risk factor for vascular disease, may play a role in the thrombotic risk of patients with PV and ET. The identification of plasma markers translating the hemostatic imbalance in patients with PV and ET would be extremely helpful in order to define the subgroup of patients with a significant clinical risk of thrombosis. |
| format | Article |
| id | doaj-art-1973bb4f586b4ae7b9b5dd72cd918ce6 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-1973bb4f586b4ae7b9b5dd72cd918ce62025-08-20T03:55:48ZengWileyThe Scientific World Journal1537-744X2011-01-01111131113710.1100/tsw.2011.108Defining the Thrombotic Risk in Patients with Myeloproliferative NeoplasmsFabrizio Vianello0Anna Battisti1Giuseppe Cella2Marina Marchetti3Anna Falanga4Hematology and Clinical Immunology Unit, Thoracic, and Vascular Sciences Department, Padova University School of Medicine, Padova, ItalyHematology and Clinical Immunology Unit, Thoracic, and Vascular Sciences Department, Padova University School of Medicine, Padova, ItalyCardiac, Thoracic, and Vascular Sciences Department, Padova University School of Medicine, Padova, ItalyDivision of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, ItalyDivision of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, ItalyPolycythemia vera (PV) and essential thrombocythemia (ET) are two Philadelphia-negative myeloproliferative neoplasms (MPN) associated with an acquired mutation in the JAK2 tyrosine kinase gene. There is a rare incidence of progression to myelofibrosis and myeloid metaplasia in both disorders, which may or may not precede transformation to acute myeloid leukemia, but thrombosis is the main cause of morbidity and mortality. The pathophysiology of thrombosis in patients with MPN is complex. Traditionally, abnormalities of platelet number and function have been claimed as the main players, but increased dynamic interactions between platelets, leukocytes, and the endothelium do probably represent a fundamental interplay in generating a thrombophilic state. In addition, endothelial dysfunction, a well-known risk factor for vascular disease, may play a role in the thrombotic risk of patients with PV and ET. The identification of plasma markers translating the hemostatic imbalance in patients with PV and ET would be extremely helpful in order to define the subgroup of patients with a significant clinical risk of thrombosis.http://dx.doi.org/10.1100/tsw.2011.108 |
| spellingShingle | Fabrizio Vianello Anna Battisti Giuseppe Cella Marina Marchetti Anna Falanga Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms The Scientific World Journal |
| title | Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms |
| title_full | Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms |
| title_fullStr | Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms |
| title_full_unstemmed | Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms |
| title_short | Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms |
| title_sort | defining the thrombotic risk in patients with myeloproliferative neoplasms |
| url | http://dx.doi.org/10.1100/tsw.2011.108 |
| work_keys_str_mv | AT fabriziovianello definingthethromboticriskinpatientswithmyeloproliferativeneoplasms AT annabattisti definingthethromboticriskinpatientswithmyeloproliferativeneoplasms AT giuseppecella definingthethromboticriskinpatientswithmyeloproliferativeneoplasms AT marinamarchetti definingthethromboticriskinpatientswithmyeloproliferativeneoplasms AT annafalanga definingthethromboticriskinpatientswithmyeloproliferativeneoplasms |